Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Long-Term Investments: 2015-2019

Historic Long-Term Investments for Lineage Cell Therapeutics (LCTX) over the last 4 years, with Dec 2019 value amounting to $19.0 million.

  • Lineage Cell Therapeutics' Long-Term Investments fell 6.40% to $19.0 million in Q4 2019 from the same period last year, while for Dec 2019 it was $19.0 million, marking a year-over-year decrease of 6.40%. This contributed to the annual value of $19.0 million for FY2019, which is 6.40% down from last year.
  • Lineage Cell Therapeutics' Long-Term Investments amounted to $19.0 million in Q4 2019, which was up 7.34% from $17.7 million recorded in Q3 2019.
  • Lineage Cell Therapeutics' 5-year Long-Term Investments high stood at $110.8 million for Q3 2017, and its period low was $4.4 million during Q1 2016.
  • For the 3-year period, Lineage Cell Therapeutics' Long-Term Investments averaged around $50.6 million, with its median value being $40.3 million (2018).
  • In the last 5 years, Lineage Cell Therapeutics' Long-Term Investments spiked by 2,041.70% in 2016 and then slumped by 70.25% in 2018.
  • Over the past 5 years, Lineage Cell Therapeutics' Long-Term Investments (Quarterly) stood at $4.7 million in 2015, then skyrocketed by 2,041.70% to $100.0 million in 2016, then crashed by 31.79% to $68.2 million in 2017, then crashed by 70.25% to $20.3 million in 2018, then declined by 6.40% to $19.0 million in 2019.
  • Its last three reported values are $19.0 million in Q4 2019, $17.7 million for Q3 2019, and $36.5 million during Q2 2019.